Request Demo
Mercury Bio and Meta-Flux Announce Strategic Collaboration to Advance Large-Molecule Therapeutics for Parkinson's and Alzheimer's Diseases
19 Dec 2025
SANTA FE, N.M. and CAMBRIDGE, Mass., Dec. 19, 2025 /PRNewswire/ -- Mercury Bio, a biotechnology company advancing large-molecule therapeutics for neurodegenerative disease, and Meta-Flux, an AI-powered disease simulation company, have announced a strategic collaboration to accelerate the development of new therapeutic programs for central nervous system (CNS) disorders, beginning with Parkinson's disease and Alzheimer's disease.
Continue Reading
Meta-Flux
The collaboration is focused on strengthening Mercury Bio's therapeutic pipeline by improving target selection, pathway prioritization, and early development decision-making for diseases driven by intracellular pathology, areas where conventional therapies have largely been limited to symptomatic treatment.
To support these therapeutic efforts, the collMercury Bioombines Mercury Bio's patented yeast extracellular vesicle (yEV™) technology - designed to deliver therapeutic proteins, RNA, and other large-molecule biologics into neurons, release them into the cytoplasm, and avoid endosomal degradation, including across the blood–brain barrier - with Meta-Flux's disease-scale computational modeling platform, which combines multi-omics data and systems-biology approaches to map pathway dynamics and cellular state changes in neurodegenerative disease, including their response to yEV-mediated delivery. Together, these capabilities are intended to enable more precise interrogation of disease biology and higher-confidence advancement of CNS drug candidates.
"Therapeutic progress in Parkinson's and Alzheimer's diseases hasMercury Biorained by four fundamental challenges: crossing the blood–brain barrier, entering the neuron, releasing the drug into the cytoplasm while avoiding endosomal degradation, and targeting the intracellular pathways that drive disease," said Bruce McCormick, Chief Executive Officer of Mercury Bio. "Our focus at Mercury Bio is on advancing therapeutics that address those intracellular mechanisms. The yEV technology supports that goal, and Meta-Fluxneurodegenerative diseaselligence needed to ensure we are targeting the right pathways with confidence."
Meta-Flux's platform integrates multi-omics data and disease-scale simulations to model how neuronal pathways respond to therapeutic intervention, enabling more informed program design and biomarker strategies in direct support of Mercury Bio's CNS therapeutics.Mercury BioMercury Bio
"This partnership allows us to evaluate disease mechanisms and therapeutic hypotheses in a context that has historically been inaccessible," said Lee Sherlock, Chief Executive Officer of Meta-Flux. "By applying our modeling framewoMercury Biory Bio's CNS programs, we can help strengthen the biological rationale behind advancing large-molecule therapeutics for neurodegenerative disease."
The collaboration reflects a shared commitment to building a more disciplined, data-driven approach to advancing therapeutics for diseases of the brain.Meta-FluxMercury Bioneurodegenerative disease
Contact:diseases of the brain
Kaelie Barnard | Director of Marketing, Barson Corp.
[email protected] | 516-712-6050
Meta-Flux | Corporate Communications [email protected]
SOURCE Mercury Bio Inc. & Meta-Flux
more press release views with
Request a Demo
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Drugs
-Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!